AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01303861
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy Groups:~1. For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~2. For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~1. For smokers with high baseline CO: 42 mg/24 h for 1 week~2. For smokers with low baseline CO: 21 mg/24 h for 1 week
Trial: NCT01303861
Drug: Nicotine Inhaler
RxNorm normalized name: nicotine Inhalation Solution
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine inhaler to use as needed after quit date
Trial: NCT00659360
Drug: saracatinib
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01978418
Drug: salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication given once as a dose of 4 puffs at 30-60 minutes of age
Trial: NCT00799006
Drug: PF-04620110
RxNorm normalized name: PF-04620110
DrugBank: PF-04620110 (DB14887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
Trial: NCT04115449
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes
Trial: NCT00384033
Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg tablet, once daily dosing for 8 weeks
Trial: NCT00384033
Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg tablet, once daily dosing for 8 weeks
Trial: NCT00384033
Drug: Duloxetine 60 mg/day
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg capsule, once daily dosing for 8 weeks
Trial: NCT01618266
Drug: dexamethasone intravitreal implant
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
Trial: NCT01919294
Drug: testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
Trial: NCT03270644
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT03270644
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03849365
Drug: TOOKAD VTP
RxNorm normalized name: VTP-201227
DrugBank: VTP-201227 (DB05652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
Trial: NCT01384695
Drug: Fluorescein
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluorescent contrast agent, Fluorescein 5ml
Trial: NCT01173757
Drug: PF-04995274
RxNorm normalized name: PF-04995274
DrugBank: PF-04995274 (DB12675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
Trial: NCT01384695
Drug: Proflavine hemisulfate
RxNorm normalized name: Proflavine hemisulfate
DrugBank: Proflavine (DB01123)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
Trial: NCT03099174
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock
Trial: NCT01134731
Drug: paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1-5 mg daily (QD)
Trial: NCT01134731
Drug: lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300-1500mg QD
Trial: NCT00215748
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01298310
Drug: Xylocaine
RxNorm normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/mL solution for injection
Trial: NCT01298310
Drug: Xylocaine
RxNorm normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/mL solution for injection
Trial: NCT00689078
Drug: Loteprednol Etabonate 0.2%
RxNorm normalized name: LOTEPREDNOL ETABONATE 0.2% SUSP,OPH
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Trial: NCT04284852
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PARP inhibitor
Trial: NCT00815607
Drug: INXN-1001
RxNorm normalized name: DNA (RECOMBINANT LENTIVIRUS VECTOR INXN-2004-TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO
DrugBank: Dabocemagene autoficel (DB17878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules given once daily for 14 days for 3 treatment cycles.
Trial: NCT01856907
Drug: Sitagliptin-Metformin
RxNorm normalized name: linagliptin / metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
Trial: NCT01856907
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Biguanide- insulin sensitizer
Trial: NCT00394160
Drug: MK0476, Montelukast Sodium /Duration of Treatment : 14 Days
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02758171
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02758171
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01424709
Drug: Gemcitabine, Docetaxel, CPT-11,Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
Trial: NCT00735683
Drug: ATHX-105 phosphate
RxNorm normalized name: calcium phosphate 105 MG
DrugBank: ATHX-105 (DB06008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: includes diet, physical activity, and lifestyle modification
Trial: NCT00704223
Drug: biphasic insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
Trial: NCT01424709
Drug: gemcitabine/cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
Trial: NCT00736814
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously
Trial: NCT00736814
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously
Trial: NCT00736814
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously
Trial: NCT00736814
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously
Trial: NCT00737438
Drug: epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. \> 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery.
Trial: NCT02307383
Drug: Lactitol
RxNorm normalized name: Lactitol
DrugBank: Lactitol (DB12942)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02307383
Drug: Lactobacillus
RxNorm normalized name: lactobacillus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01986946
Drug: Dilaudid
RxNorm normalized name: Dilaudid
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
Trial: NCT01944033
Drug: Bricanyl
RxNorm normalized name: Bricanyl
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
Trial: NCT00735241
Drug: Bevacizumab cycles 3 onwards
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy
Trial: NCT03099174
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort D) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
Trial: NCT01561378
Drug: Aspart insulin
RxNorm normalized name: Aspart Insulin
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
Trial: NCT01787474
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01787474
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01460368
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00085904
Drug: SB-485232
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00014261
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00071396
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 IV infusion on day 1, then 500 mg/m\^2 on days 8, 15, and 22.
Trial: NCT00815399
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-45 mg/die
Trial: NCT00815399
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500-2000 mg/die
Trial: NCT03503136
Drug: nedaplatin
RxNorm normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
Trial: NCT03503136
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
Trial: NCT02173873
Drug: ziv-aflibercept drug
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
Trial: NCT00669396
Drug: Copper T380 IUD
RxNorm normalized name: copper
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper T380 IUD
Trial: NCT00669396
Drug: levonorgestrel
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.5 mg
Trial: NCT00300105
Drug: Tesaglitazar
RxNorm normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01715935
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
Trial: NCT00810693
Drug: Riociguat (Adempas, BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
Trial: NCT00810693
Drug: Riociguat (Adempas, BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BAY63-2521: 1.5mg tid orally for 12 weeks
Trial: NCT03624231
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
Trial: NCT03624231
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (75 mg) for up to 4 doses/cycles
Trial: NCT02819869
Drug: Statin and Metformin use
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00794261
Drug: Injection of Pegfilgrastim
RxNorm normalized name: pegfilgrastim Injection
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
Trial: NCT01768767
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01768767
Drug: Ketamine/Lithium
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00769522
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cycle 1-6: 90mg/m² i.v., day 1-2, q28d
Trial: NCT00769522
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
Trial: NCT04178798
Drug: Acalabrutinib 100 MG Oral Capsule
RxNorm normalized name: Acalabrutinib 100 mg oral capsule
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.
Trial: NCT00794261
Drug: Injection of Filgrastim
RxNorm normalized name: filgrastim Injection
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN \> 0.5 G/L)
Trial: NCT04148391
Drug: NYX-458
RxNorm normalized name: NYX-2925
DrugBank: NYX-2925 (DB19149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Trial: NCT03796533
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * PCZ will be used as recommended in tablet formulation at an initial dosage of 300 mg twice a day on the first day and then once a day at a dose of 300 mg the following days.~* PCZ prophylaxis will be started on the same day as the start of chemotherapy and will be continued until the end of aplasia.~* The dosage of the PCZ can be adjusted according to the results of the PCZ assay. It may be interrupted if the transaminase level is greater than 3 times higher than normal (3N) or on medical decision.
Trial: NCT02572609
Drug: Ambroxol hydrochloride soft pastille
RxNorm normalized name: ambroxol hydrochloride
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00295893
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00295893
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00295893
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT03548428
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200mg IV every 3 weeks for 4 months
Trial: NCT02979197
Drug: OE 10 mg amlodipine besylate tablet
RxNorm normalized name: amlodipine 10 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02979197
Drug: Matched placebo for OE amlodipine besylate tablet
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04173949
Drug: Ramipril 2.5 MG
RxNorm normalized name: ramipril 2.5 MG
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 month of treatment with daily Ramipril 2.5 MG
Trial: NCT01828879
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
Trial: NCT00989157
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 60 mg of duloxetine
Trial: NCT00702533
Drug: Pentagastrin
RxNorm normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03859635
Drug: Liposomal Bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml
Trial: NCT02081183
Drug: Mycophenolate mofetil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
Trial: NCT03859635
Drug: Bupivacaine, 0.25%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml
Trial: NCT03859635
Drug: Bupivacaine, 0.5%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 ml
Trial: NCT02081183
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
Trial: NCT03519971
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab IV (intravenous infusion)
Trial: NCT00003927
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003927
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes